Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Liana Gercheva-Kyuchukova"'
Autor:
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian
Publikováno v:
HemaSphere, Vol 7, p e216416f (2023)
Externí odkaz:
https://doaj.org/article/4d7243c8e5154d6eb203cf6a0a30256f
Autor:
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Viktor Rossiev, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian, for the PROUD-PV Study Group
Publikováno v:
HemaSphere, Vol 4, Iss 6, p e485 (2020)
Externí odkaz:
https://doaj.org/article/5fda375d5298471dabb1ce29d4ebc970
Autor:
Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Robert Kralovics, Heinz Gisslinger
Publikováno v:
Blood. 140:9663-9664
Autor:
Ella Willenbacher, Zita Borbényi, Steffen Koschmieder, Robert Kralovics, Mario Cazzola, Uwe Platzbecker, Emanuil Gheorghita, Pencho Georgiev, Heinz Gisslinger, Mathieu Puyade, Malgorzata Calbecka, Jerome Rey, Kurt Krejcy, Jiri Mayer, Krzysztof Warzocha, Emilie Cayssials-Caylus, Veronika Buxhofer-Ausch, János Jakucs, Anna Vallova, Georgi Mihaylov, Hans Carl Hasselbalch, Lydia Roy, Vera Yablokova, Olga Cerna, Aleksander Skotnicki, Richard Greil, Jiri Schwarz, Vera Stoeva, Lylia Sivcheva, Zvenyslava Masliak, Halyna Pylypenko, Antonia Hatalova, Delia Dima, Jose Miguel Torregrosa-Diaz, Elena Volodicheva, Jean-Jacques Kiladjian, S V Klymenko, Carlos Besses Raebel, Polina Kaplan, Irina Sokolova, Horia Bumbea, Miklos Egyed, Nicoleta Berbec, Barbara Grohmann-Izay, Alexander Myasnikov, Petr Dulicek, Tamila Lysa, Dominik Wolf, Andrei Cucuianu, Christoph Klade, Mihaela Lazaroiu, Maria Soroka-Wojtaszko, Tamás Masszi, Ernst Forjan, Liana Gercheva-Kyuchukova, Franz Bauer, Dorota Krochmalczyk, Árpád Illés, Mikulas Hrubisko, Jolanta Starzak-Gwozdz, Viktor Rossiev
Publikováno v:
The Lancet Haematology. 7:e196-e208
Summary Background The PROUD-PV and CONTINUATION-PV trials aimed to compare the novel monopegylated interferon ropeginterferon alfa-2b with hydroxyurea, the standard therapy for patients with polycythaemia vera, over 3 years of treatment. Methods PRO
Autor:
Liana Gercheva-Kyuchukova, Huy Van Nguyen, Tim Mant, Catherine Bagot, Baisong Mei, Qifeng Yu, Margaret V. Ragni, Craig Benson, Kate Madigan, Toshko Lissitchkov, K. John Pasi, Margarita Timofeeva, Pratima Chowdary, Pencho Georgiev, Vasily Mamonov
Publikováno v:
Journal of Thrombosis and Haemostasis
Background Fitusiran, an investigational small interfering RNA therapy, reduces antithrombin production to rebalance hemostasis in people with hemophilia A or B, with or without inhibitors. Objectives To evaluate the safety and efficacy of fitusiran
Autor:
Pierre Fenaux, Iordanis Milionis, Mathilde Hunault Berger, Achilles Anagnostopoulos, Robert Wapenaar, Atanas Radinoff, Maria Antonietta Aloe Spiriti, Valeria Santini, Aristoteles Giagounidis, Argiris Symeonidis, Esther Oliva, Rudolf Schlag, Hari Haralampiev, Liana Gercheva-Kyuchukova, Katharina Götze, Uwe Platzbecker, Anna Potamianou
Publikováno v:
Leukemia
Erythropoiesis-stimulating agents are first choice for treating anemia in low-risk MDS. This double-blind, placebo-controlled study assessed the efficacy and safety of epoetin-α in IPSS low- or intermediate-1 risk (i.e., low-risk) MDS patients with
Autor:
Liana Gercheva-Kyuchukova, Robert Kralovics, Heinz Gisslinger, Miklos Egyed, Árpád Illés, Christoph Klade, Hans Carl Hasselbalch, Lylia Sivcheva, Pencho Georgiev, Kurt Krejcy, Dorota Krochmalczyk, Jiri Mayer, Jean-Jacques Kiladjian, Vera Yablokova, Halyna Pylypenko, Petr Dulíček, Victoria Empson
Publikováno v:
Blood. 138:3660-3660
Introduction: Ropeginterferon alfa-2b (BESREMi®), a novel pegylated interferon with an extended half-life, was approved in Europe for treatment of patients with PV based on results from the phase 3 PROUD-PV and CONTINUATION-PV trials. Ropeginterfero
Autor:
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Viktor Rossiev, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Barbara Grohmann-Izay, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian, PROUD-PV Study Group
Publikováno v:
SSRN Electronic Journal.
Background: Ropeginterferon alfa-2b (ropeg) is a novel, mono-pegylated interferon (IFN) for treatment of polycythemia vera (PV). The PROUD-PV/CONTINUATION-PV trial compared ropeg with hydroxyurea (HU), the standard therapy for PV, over three years of
Autor:
Lylia Sivcheva, Hans Carl Hasselbalch, Jean-Jacques Kiladjian, Liana Gercheva-Kyuchukova, Christoph Klade, Pencho Georgiev, Victoria Empson, Robert Kralovics, Heinz Gisslinger, Árpád Illés, Miklos Egyed, Jiří Mayer, Halyna Pylypenko, Petr Dulíček, Kurt Krejcy, Dorota Krochmalczyk, Vera Yablokova
Publikováno v:
Blood. 136:33-33
Introduction: Patients with polycythemia vera (PV) require life-long treatment to prevent thromboembolic events and minimize the risk of progression. Ropeginterferon alpha-2b (BESREMi®; hereafter ropeg) may ultimately modify the natural history of P
Autor:
Liana Gercheva-Kyuchukova, Miklos Egyed, Vera Yablokova, Christoph Klade, Viktor Rossiev, Heinz Gisslinger, Halyna Pylypenko, Hans Carl Hasselbalch, Lylia Sivcheva, Petr Dulíček, Kurt Krejcy, Jean-Jacques Kiladjian, Dorota Krochmalczyk, Jiri Mayer, Pencho Georgiev, Robert Kralovics, Árpád Illés
Publikováno v:
Blood. 134:553-553
Introduction: The key treatment goals for polycythemia vera (PV) are to prevent thromboembolic events and minimize the risk of progression, ultimately modifying the natural history of the disease by selectively targeting the malignant clone. In the P